利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

75 条记录 (耗时 0.045 秒)

    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
    5.
    发明公开
    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 审中-公开
    方法和组合物诊断和预后判断肾功能衰竭和肾损害

    公开(公告)号：EP3077819A1

    公开(公告)日：2016-10-12

    申请号：EP14868424.4

    申请日：2014-12-03

    申请人： Astute Medical, Inc. ,  University of Pittsburgh - Of the Commonwealth System of Higher Education

    发明人： MCPHERSON, Paul ,  KELLUM, John, A.

    IPC分类号： G01N33/566

    CPC分类号： A61K38/13 ,  A61K31/357 ,  A61K31/366 ,  A61K31/436 ,  A61K31/437 ,  A61K31/453 ,  A61K31/55 ,  A61K31/585 ,  A61K38/1754 ,  A61K38/55 ,  A61K45/06 ,  G01N33/6893 ,  G01N2333/4745 ,  G01N2333/8146 ,  G01N2800/347 ,  G01N2800/50

    摘要： It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G
    0 /G
    1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G
    0 /G
    1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.

    摘要翻译： 它是本发明的一个目的是通过治疗受试者与化合物做调节细胞周期以提供用于从急性肾损伤的受试者的保护方法和组合物。 调节细胞周期可以包括诱导G0 / G1期细胞周期停滞和/或诱导细胞周期进程。 如以下实例阐述，其诱导G0 / G1细胞周期阻滞可以保护受试者从AKI，并且可以提前的预防性使用，或作为治疗以下的化合物的甚至单次给药，各种处理或条件也已知是有害 肾脏，通过逮捕任选发行紧随其后。 一旦AKI被建立，细胞周期进程可以被诱导以增加替换丢失和损坏细胞的

    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
    9.
    发明公开
    METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE 审中-公开
    肾损伤和肾功能衰竭的诊断和预后的方法和组合物

    公开(公告)号：EP3249402A1

    公开(公告)日：2017-11-29

    申请号：EP17175396.5

    申请日：2011-10-06

    申请人： Astute Medical, Inc.

    发明人： ANDERBERG, Joseph ,  GRAY, Jeff ,  MCPHERSON, Paul ,  NAKAMURA, Kevin ,  KAMPF, James Patrick

    IPC分类号： G01N33/53

    CPC分类号： G01N33/6893 ,  G01N2800/347 ,  G01N2800/52 ,  G01N2800/56

    摘要： The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using assays that detect Follistatin, and optionally further one or more biomarkers selected from the group consisting of Beta-nerve growth factor, Interleukin-17A, Follitropin subunit beta, Collagenase 3, Vitamin D Binding Protein, Islet amyloid polypeptide, Insulin C-peptide, Complement Factor H, Gastric inhibitory polypeptide, Glucagon-like peptide 1, Glucagon, Involucrin, Type II cytoskeletal Keratin-1/Keratin-10, Type II cytoskeletal Keratin-6A/6B/6C, Osteocalcin, Lipopolysaccharide, Pancreatic prohormone, Peptide YY, Agouti-related protein, Ciliary neurotrophic factor, Appetite-regulating hormone, Transthyretin, Insulin receptor substrate 1, and NF-kappa-B inhibitor alpha as diagnostic and prognostic biomarker assays in renal injuries.

    摘要翻译： 本发明涉及用于监测，诊断，预后和确定患有或怀疑患有肾损伤的受试者的治疗方案的方法和组合物。 具体而言，本发明涉及使用检测Follistatin以及任选地进一步选自β神经生长因子，白细胞介素-17A，促卵泡素亚基β，胶原酶3，维生素D结合蛋白，胰岛淀粉样蛋白的组中的一种或多种生物标记的测定 多肽，胰岛素C-肽，补体因子H，胃抑制性多肽，胰高血糖素样肽1，胰高血糖素，Involucrin，II型细胞骨架角蛋白-1 /角蛋白-10，II型细胞骨架角蛋白-6A / 6B / 6C，骨钙素，脂多糖 ，胰激肽原，肽YY，刺鼠相关蛋白，睫状神经营养因子，食欲调节激素，转甲状腺素蛋白，胰岛素受体底物1和NF-κB抑制剂α作为肾损伤诊断和预后生物标志物测定。